155 related articles for article (PubMed ID: 36536266)
1. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy.
Rossi F; Lambertini M; Brunetti N; De Giorgis S; Razeti MG; Calabrese M; Tagliafico AS
Radiol Med; 2023 Jan; 128(1):49-57. PubMed ID: 36536266
[TBL] [Abstract][Full Text] [Related]
2. Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area.
Rossi F; Torri L; Lambertini M; De Giorgis S; Calabrese M; Tagliafico AS
Eur Radiol; 2020 Aug; 30(8):4234-4241. PubMed ID: 32232787
[TBL] [Abstract][Full Text] [Related]
3. Muscle mass estimation on breast magnetic resonance imaging in breast cancer patients: comparison between psoas muscle area on computer tomography and pectoralis muscle area on MRI.
Rossi F; Valdora F; Barabino E; Calabrese M; Tagliafico AS
Eur Radiol; 2019 Feb; 29(2):494-500. PubMed ID: 30088069
[TBL] [Abstract][Full Text] [Related]
4. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer.
Baysal H; Serdaroglu AY; Ozemir IA; Baysal B; Gungor S; Erol CI; Ozsoy MS; Ekinci O; Alimoglu O
J Surg Res; 2022 Oct; 278():223-232. PubMed ID: 35636197
[TBL] [Abstract][Full Text] [Related]
6. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
7. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P
Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303
[TBL] [Abstract][Full Text] [Related]
8. Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists.
Tang WJ; Chen SY; Hu WK; Li XL; Zheng BJ; Wang ZS; Ding HJ; Chen LX; Zhang QQ; Yu XM; Sui Y; Wei XH; Guo Y
AJR Am J Roentgenol; 2023 Jun; 220(6):817-825. PubMed ID: 36752371
[No Abstract] [Full Text] [Related]
9. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
10. Time Course Changes of Synthetic Relaxation Time During Neoadjuvant Chemotherapy in Breast Cancer: The Optimal Parameter for Treatment Response Evaluation.
Zhao R; Du S; Gao S; Shi J; Zhang L
J Magn Reson Imaging; 2023 Oct; 58(4):1290-1302. PubMed ID: 36621982
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
[TBL] [Abstract][Full Text] [Related]
12. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
[TBL] [Abstract][Full Text] [Related]
13. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
14. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
15. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
17. Can unenhanced MRI of the breast replace contrast-enhanced MRI in assessing response to neoadjuvant chemotherapy?
Cavallo Marincola B; Telesca M; Zaccagna F; Riemer F; Anzidei M; Catalano C; Pediconi F
Acta Radiol; 2019 Jan; 60(1):35-44. PubMed ID: 29742918
[TBL] [Abstract][Full Text] [Related]
18. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of breast ultrasonography and MRI in the prediction of lymph node status after neoadjuvant chemotherapy for breast cancer.
Ha SM; Cha JH; Kim HH; Shin HJ; Chae EY; Choi WJ
Acta Radiol; 2017 Oct; 58(10):1198-1205. PubMed ID: 28350255
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
